Covid-19 Takes a Center Stage in R&D of Respiratory Tract Infection Treatment
Respiratory tract infections are often separated into the three
basic categories. Upper respiratory system infections: These include colds and
the flu. Lower respiratory system infections: These include bronchitis,
pneumonia, and other serious respiratory conditions. Viral respiratory
infections are also commonly grouped into three categories. They include
bronchitis (which are often a sign of bronchial pneumonia), the flu, and the
flu-like illnesses. Other respiratory infections include sinusitis, which can
be caused by a virus that enters the respiratory system through a nasal or
throat opening. A bacterial respiratory infection can affect any part of the
respiratory system and can even affect organs other than the respiratory
system. These infections include lung infections, like bronchitis, pneumonia,
and tuberculosis. A sinus infection can cause symptoms similar to those of a cold,
such as fever, headache, and cough.
Respiratory
tract infection treatment is determined by the type of infection you have.
Your doctor will order tests to rule out other possibilities before
recommending the proper treatment. In some cases, a simple over-the-counter
nasal spray can relieve some of your symptoms, while in other cases a prescription
medication may be needed. If the problem is bac
terial, your doctor may
prescribe the proper treatment to kill the infection. Antibiotics are often
prescribed. But in some cases, your doctor may treat the problem naturally,
using home remedies or natural methods.
Covid-19 has taken a center stage in R&D of respiratory tract
infection treatment. Covid-19 is a new respiratory tract infection caused by
SARS-CoV-2. The disease has globally, as of 7:03pm CET, 25 November 2020, there
have been 59,481,313 confirmed cases of COVID-19, including 1,404,542 deaths,
reported to the World Health Organization. In terms of region, the Americas are
leading the count followed by South-east Asia and Europe. The U.S accounted for
over 12.8 million active cases. As of September 2020, there were 321 vaccine
candidates in development, which accounted for a 2.5X increase since April
2020. 22 vaccines are in small-scale safety trials (Phase 1); 25 are in
expanded safety trials (Phase 2); 25 are in large-scale efficacy trials (Phase
3); and 4 vaccines are in Phase 4.
Comments
Post a Comment